Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors

Bibliographic Details
Main Authors:	Chang-Lin, Joan-En, Batoosingh, Amy L, Hollander, David A, Schiffman, Rhett M, Tang-Liu, Diane D-S
Format:	Online
Language:	English
Published:	Dove Medical Press 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162290/

Similar Items

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
by: Day, Douglas G, et al.
Published: (2013)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
by: Myers, Jonathan S, et al.
Published: (2014)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
by: Shafiee, Afshin, et al.
Published: (2013)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
by: Goldberg, Ivan, et al.
Published: (2014)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
by: Pfennigsdorf, Stefan, et al.
Published: (2016)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
by: Mishra, Deepak, et al.
Published: (2014)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Published: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Published: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
by: Tsumura, Toyoaki, et al.
Published: (2012)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
by: Inoue, Kenji, et al.
Published: (2014)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
by: Pillunat, Lutz E, et al.
Published: (2016)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
by: Pfennigsdorf, Stefan, et al.
Published: (2012)

An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
by: Nixon, Donald R, et al.
Published: (2012)

Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure
by: Tung, Jonathan D, et al.
Published: (2012)

Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting
by: Park, Ki Ho, et al.
Published: (2014)

Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
by: Chen, Ying Ying, et al.
Published: (2016)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
by: Schnober, Dietmar, et al.
Published: (2015)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
by: Wirta, David, et al.
Published: (2011)

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
by: Wang, Kaidi, et al.
Published: (2014)

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan® RC Early Analysis Review (CLEAR) trial
by: Crichton, Andrew C, et al.
Published: (2014)

A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
by: Natt, Navreet Kaur, et al.
Published: (2014)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
by: Campbell, Joanna H, et al.
Published: (2014)

Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial
by: Oddone, Francesco, et al.
Published: (2015)

Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
by: DuBiner, Harvey B, et al.
Published: (2014)

Treatment of balanitis of Zoon's with tacrolimus 0.03% ointment
by: Chander, Ram, et al.
Published: (2009)

In-gap quasiparticle excitations induced by non-magnetic Cu impurities in Na(Fe0.96Co0.03Cu0.01)As revealed by scanning tunnelling spectroscopy
by: Yang, Huan, et al.
Published: (2013)

Thermal activation energy of 3D vortex matter in NaFe1−x Co x As (x = 0.01, 0.03 and 0.07) single crystals
by: W. J. Choi, et al.
Published: (2017-09-01)

An Effect of Bimatoprost: Adverse for Some, Therapeutic for Others
by: Dubey, Ashok Kumar
Published: (2011)

Bimatoprost in the Treatment of Eyelash Universalis Alopecia Areata
by: Vila, Teresa Ojeda, et al.
Published: (2010)

The biodisposition and hypertrichotic effects of bimatoprost in mouse skin
by: Woodward, David F, et al.
Published: (2013)

Periorbital muscle atrophy associated with topical bimatoprost therapy
by: Wang, Priscilla Xinhui, et al.
Published: (2014)

Tear biomarkers in latanoprost and bimatoprost treated eyes.
by: Shweta Reddy, et al.

Hirsutism following the use of bimatoprost eyedrops for glaucoma
by: Kaliaperumal, Subashini, et al.
Published: (2014)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
by: Stevens, Annemie, et al.
Published: (2016)

Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients
by: Cordeiro, M Francesca, et al.
Published: (2015)

Vortex motion in layered superconductors Cu0.03TaS2
by: Junchao Lu, et al.
Published: (2014-06-01)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
by: Inoue, Kenji, et al.
Published: (2012)

The Role of Bimatoprost Eyelash Gel in Chemotherapy-induced Madarosis: An Analysis of Efficacy and Safety
by: Morris, Carrie L, et al.
Published: (2011)

Bimatoprost for Eyelash Growth in Japanese Subjects: Two Multicenter Controlled Studies
by: Harii, K., et al.
Published: (2014)

Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
by: Chen, Wensheng, et al.
Published: (2014)